Treatment Support and Financial Assistance*
With SOMAVERT®, patients receive comprehensive support services
Pfizer offers comprehensive services for your patients, including financial assistance for eligible patients, if needed. You can enroll your patients by calling the Pfizer Bridge Program® at 1-800-645-1280, or fax a completed Statement of Medical Necessity (SMN) to 1-800-479-2562.
The Pfizer Bridge Program
Provides comprehensive support to help expedite the initiation of therapy, help patients afford therapy, and help patients stay on therapy.
A dedicated Patient Care Consultant (PCC) is assigned to coordinate care between your patient and their family, their insurance company and pharmacy, and your office.
The same PCC works with your patients from SMN initiation throughout the reimbursement process, during insurance change, and at the time of reauthorization. The PCC also works with your patients to help fill their initial SOMAVERT prescription, arrange injection training (when requested), and more. For more information, call the Pfizer Bridge Program at 1-800-645-1280.
*Powered by Pfizer Helpful Answers®.
SOMAVERT Copay/Coinsurance Support Program*†
The expanded SOMAVERT Copay/Coinsurance Support Program now offers up to $5000/year in assistance for commercially insured patients
- Patients pay just $5 per month and the rest of their copay/coinsurance is covered For more information call Pfizer at 1-800-645-1280
*The SOMAVERT Copay/Coinsurance Support Program is not health insurance. This copay/coinsurance is only available at participating pharmacies. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. No membership fees. Some restrictions may apply.
†Includes copay and coinsurance; excludes deductible.
SOMAVERT Patient Assistance Program
Qualified uninsured or underinsured patients can receive SOMAVERT and supplies at no cost. For more information, call the Pfizer Bridge Program at 1-800-645-1280.
SOMAVERT Starter Kit
To help new patients begin SOMAVERT therapy, Pfizer supplies a kit containing several helpful tools. These include a SOMAVERT Injection Placemat, Patient Brochure, injection training DVD, and an initial supply of syringes for injecting SOMAVERT (when a prescription is provided).
Patients can get one-on-one in-home training by qualified nurses. To request training for your patient during enrollment, simply check the “Patient Injection Training Requested” box on the SOMAVERT Statement of Medical Necessity.
SOMAVERT (pegvisomant for injection) is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum IGF-I levels.
Important Safety Information for SOMAVERT
SOMAVERT is contraindicated in patients with a history of hypersensitivity to any of its components.
Patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
Functional effects of increased GH are prevented by GH receptor blockade; therefore, patients on SOMAVERT should be carefully observed for the clinical signs and symptoms of a GH-deficient state.
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
Important safety information regarding periodic tumor size monitoring
Tumors that secrete GH may expand and cause serious complications. All patients with GH-secreting tumors, including those receiving SOMAVERT, should be carefully monitored for changes in tumor volume. Overall, mean tumor size was unchanged during the course of treatment in clinical studies. Tumor volume change did not appear to be influenced by whether or not patients had previously received radiation therapy.
Important safety information regarding liver test monitoring
Monitor liver tests based on baseline values and changes during therapy according to the schedule in the full prescribing information. In clinical studies with SOMAVERT, ALT was >3X but <10X the upper limit of normal (ULN) in patients treated with SOMAVERT (1.2%) vs placebo (2.1%). ALT and AST elevations occurred within 4 to 12 weeks after the start of therapy and did not appear to be related to the dose. 2 patients (0.8%) experienced elevations of ALT and AST serum concentrations >10X the upper limit of normal (ULN). In both patients, the elevations normalized after discontinuation of the medicine. If a patient develops liver test elevations, or any other symptoms of liver dysfunction while receiving SOMAVERT, please see Liver Tests section of full Prescribing Information.
In subjects with systemic hypersensitivity reactions, caution and close monitoring should be exercised when re-initiating SOMAVERT therapy.
The most common adverse events (>10% and at frequencies greater than placebo) in 1 of the 3 active treatment arms in a 12-week placebo-controlled study (N=112) included infection, pain, diarrhea, nausea, flu syndrome, abnormal liver function tests, and injection-site reaction.
Injection sites should be rotated daily to help prevent lipohypertrophy.
The maximum indicated daily maintenance dose for SOMAVERT is 30 mg.